ADDvise Group has entered into a share purchase agreement with the owners of Kolplast CI S.A. (“Kolplast”) regarding the acquisition of all shares of Kolplast in accordance with the letter of intent previously communicated. Closing of the acquisition is expected to take place during the fourth quarter of 2023.
Kolplast’s revenue for the last twelve months per August 31, 2023 amounted to BRL 101.9 million, with an EBITDA of BRL 29.8 million, corresponding to an EBITDA margin of 29.3 per cent.
The acquisition will be consummated at an initial cash consideration of BRL 160 million and conditional and performance-based payments expected to amount to BRL 50 million in aggregate over a three-year period.
The acquisition is financed through own funds. ADDvise assesses that the acquisition will have a positive impact on ADDvise’s earnings per share during the financial year 2023.
Kolplast, based in São Paulo, Brazil, is a leading manufacturer and provider of MedTech equipment. The company produces disposable medical devices, MedTech equipment, laboratory equipment, and liquid-based cytology products.
For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se
Hanna Myhrman, General Counsel
+46 709 82 92 23
hanna.myhrman@addvisegroup.se
About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.